Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer

Journal of Immunotherapy

Volumn 32, Issue 1, 2009, Pages 92-99

  Neninger, Elia ^a   Verdecia, Beatriz Garcí ^b   Crombet, Tania ^b   Viada, Carmen ^b   Pereda, Susana ^b   Leonard, Idrissa ^b   Mazorra, Zaima ^b   Fleites, Gladys ^a   González, Marta ^a   Wilkinson, Bárbara ^b   González, Gisela ^b   Lage, Agustín ^b  

^a HOSPITAL CLINICOQUIRÚRGICO HERMANOS AMEIJEIRAS   (Cuba)

^b CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Cancer vaccine; EGF; NSCLC

Indexed keywords

CANCER VACCINE; CISPLATIN; CYCLOPHOSPHAMIDE; RECOMBINANT EPIDERMAL GROWTH FACTOR; VINBLASTINE; ALKYLATING AGENT; ANTIBODY; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; RECOMBINANT PROTEIN;

ADULT; ADVANCED CANCER; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; IMMUNOGENICITY; INJECTION SITE PAIN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; PRIORITY JOURNAL; VOMITING; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; IMMUNOLOGY; LUNG TUMOR; METABOLISM; MIDDLE AGED; PILOT STUDY;

ADULT; AGED; ANTIBODIES; ANTINEOPLASTIC AGENTS, ALKYLATING; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PILOT PROJECTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT PROTEINS;

EID: 65549127347     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31818fe167     Document Type: Article

References (32)

1. Sandler A, Gray R, Perry MC, et al. Paclitaxel-Carboplatin alone or with Bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-2550.
2. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimenns for advanced non-small-cell lung cancer. N Engl J Med. 2000;346:92-98.
3. Paccagnella A, Oniga F, Bears A, et al. Adding Gemcitabine to Paclitaxel-Carboplastin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III Study. J Clin Oncol. 2006;24:681-687.
4. Spicer J, Harper P. Targeted therapies for non-small cell lung cancer. Int J Clin Pract. 2005;59:1055-1062.
5. Neelam TS, Kris MG, Pao W, et al. Practical management of patients UIT non-small-cell lung cancer treated with Gefitinif. J Clin Oncol. 2005;23:165-174.
6. Lage A, Crombet T, González G. Targeting epidermal growth factor receptor signaling: early results and future trends in oncology. Ann Med. 2003;35:327-336.
7. Gonzalez G, Crombet T, Torres F, et al. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann Oncol. 2003;14:461-466.
8. Gonzalez G, Crombet T, Catalá M, et al. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann Oncol. 1998;9:431-435.
9. Ramos TC, Vinageras EN, Ferrer MC, et al. Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a phase I trial. Cancer Biol Ther. 2006;5:145-149.
10. González G, Crombet T, Nenínger E, et al. Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer. Analysis of a pooled data from three clinical trials. Hum Vaccines. 2007;3:8-13.
11. Neninger E, de la Torre A, Osorio M, et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol. 2008;26:1452-1458.
12. Rodriguez PC, Gonzalez I, Gonzalez A, et al. Priming and boosting determinants on the antibody response to an epidermal growth factor-based cancer vaccine. Vaccine. 2008; 26:4647-4654.
13. Lake RA, Robinson BWS. Immunotherapy and chemotherapy: a practical partnership. Nat Rev Cancer. 2005;5:397-405.
14. Bass KK, Mastrangelo MJ. Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol Immunother. 1998;47:1-12.
15. + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol. 2004;34:336-344.
16. + T cells to the antitumor immune response. J Exp Med. 2005;201:1591-1602.
17. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005;6:345-352.
18. Berd DF, Mastrangelo MJ, Engstrom PF, et al. Augmentation of the human immune response by cyclophosphamide. Cancer Res. 1982;42:4862-4866.
19. Turk JI, Parker D. Effect of cyclophosphamide on immunological control mechanisms. Immunol Rev. 1982;65:99-113.
20. Mackall CL, Hakim FT, Gress RE. Restoration of T-cell homeostasis after T-cell depletion. Semin Immunol. 1997;9: 339-346.
21. Mackall CL, Fleisher TA, Brown MR, et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood. 1994;84:2221-2228.
22. Mackall CL, Hakim FT, Gress RE. T-cell regeneration: all repertoires are not created equal. Immunol Today. 1997; 18: 245-251.
23. + T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med. 1995;332:143-149.
24. Hakim FT. Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood. 1997; 90:3789-3798.
25. Mackall CL, Bare CV, Granger LA, et al. Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J Immunol. 1996; 156: 4609-4616.
26. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
27. Gonzalez G, Montero E, Leon K, et al. Autoimmunization to epidermal growth factor, a component of the immunological homunculus. Autoimmun Rev. 2002; 1:89-95.
28. García B, Neninger E, de la Torre A, et al. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by antiepidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res. 2008;14:840-846.
29. Lage A, Perez R, Fernandez LE. Therapeutic cancer vaccines: at midway between immunology and pharmacology. Curr Cancer Drug Targets. 2005;5:611-627.
30. García B, Lage A. Immunosenescence: implications for cancer immunotherapy in elderly patients. Biotecnología Aplicada. 2006;23:186-264.
31. Gravekamp C. Cancer vaccines in old age. Exp Gerontol. 2007;42:441-450.
32. Richter A, Drummond DR, MacGarvie J, et al. Contribution of the transforming growth factor alpha B loop beta-sheet to binding and activation of the epidermal growth factor receptor. J Biol Chem. 1995;270:1612-1616.